|1.||Shapiro, Geoffrey I: 6 articles (01/2014 - 05/2006)|
|2.||Abbas, Richat: 5 articles (01/2014 - 04/2009)|
|3.||Wong, Kwok-Kin: 5 articles (08/2007 - 05/2006)|
|4.||Shimamura, Takeshi: 4 articles (07/2007 - 05/2006)|
|5.||Ji, Hongbin: 4 articles (07/2007 - 05/2006)|
|6.||Chen, Liang: 3 articles (10/2015 - 06/2006)|
|7.||Awada, Ahmad: 3 articles (12/2013 - 03/2010)|
|8.||Vermette, Jennifer: 3 articles (12/2013 - 04/2009)|
|9.||Settleman, Jeffrey: 3 articles (08/2012 - 05/2005)|
|10.||Zacharchuk, Charles: 3 articles (06/2010 - 04/2009)|
01/01/2015 - "Neratinib has been shown to be effective against HER2-overexpressing or mutant tumors in vitro and in vivo. "
01/01/2015 - "Neratinib is currently being investigated in various clinical trials in breast cancers and other solid tumors, including those with HER2 mutation. "
04/01/2012 - "This Phase 1 dose-escalation study assessed the safety, tolerability, maximum-tolerated dose, antitumor activity and pharmacokinetics of neratinib in Japanese patients with advanced solid tumors. "
04/01/2012 - "Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study."
08/01/2007 - "A phase I HKI-272 monotherapy trial in patients with solid tumors is close to completion. "
|2.||Breast Neoplasms (Breast Cancer)
09/01/2015 - "Two clinical trials of neratinib for HER2-mutated metastatic breast cancer are currently enrolling patients. "
12/01/2013 - "The study confirmed relevant single-agent clinical activity and acceptable overall tolerability of neratinib in patients with recurrent HER2+ advanced breast cancer."
06/01/2012 - "This article reviews the molecular and clinical development of neratinib, an example of a covalent drug, from preclinical models to Phase III clinical trials, focusing on breast cancer treatment. "
11/01/2009 - "Both preclinical and human studies have shown that neratinib has promising activity in both advanced breast cancer and NSCLC with an acceptable safety profile. "
09/01/2015 - "Therefore, we suggest that neratinib may be a potential therapeutic drug for treating TamR breast cancer. "
10/01/2015 - "The objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma. "
10/01/2015 - "The efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu. "
10/01/2015 - "HER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean±SEM IC50:0.014μM±0.004vs.0.164μM±0.019 p=0.0003). "
10/01/2015 - "Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo."
10/01/2015 - "The efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts. "
|4.||Lung Neoplasms (Lung Cancer)
12/01/2015 - "Patients with lung cancers harboring G719X exhibited higher response rate to afatinib or neratinib (∼80%) than to 1G TKIs (35%-56%) by compilation of data in the literature. "
12/01/2015 - "EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs."
08/01/2007 - "HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations. "
07/26/2007 - "The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272."
09/01/2015 - "Further, data from The Cancer Genome Atlas project have identified HER2 mutations in a wide range of solid tumors, including bladder, colorectal, and non-small cell lung cancers, suggesting that clinical trials of neratinib or neratinib-based combinations for HER2-mutated solid tumors is warranted."
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/01/2007 - "A phase II trial of HKI-272 in non-small cell lung cancer patients has been initiated. "
12/01/2014 - "The targeted therapies dabrafenib and neratinib are being tested separately in subsets of patients with BRAF- and HER2-mutant non-small cell lung cancer. "
11/01/2009 - "Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer."
08/01/2007 - "HKI-272 in non small cell lung cancer."
08/01/2007 - "HKI-272 might offer benefits to non-small cell lung cancer patients who have relapsed after an initial response to erlotinib."
|3.||Epidermal Growth Factor Receptor (EGF Receptor)
|7.||erlotinib (CP 358,774)
|10.||Epidermal Growth Factor (EGF)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)